121 related articles for article (PubMed ID: 37924648)
21. Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting.
Krakowski I; Bottai M; Häbel H; Masucci G; Girnita A; Smedby KE; Eriksson H
J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):105-115. PubMed ID: 32455474
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
[TBL] [Abstract][Full Text] [Related]
23. A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response.
De Wolf K; Kruse V; Sundahl N; van Gele M; Chevolet I; Speeckaert R; Brochez L; Ost P
J Transl Med; 2017 Jan; 15(1):21. PubMed ID: 28137295
[TBL] [Abstract][Full Text] [Related]
24. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.
Guinney J; Wang T; Laajala TD; Winner KK; Bare JC; Neto EC; Khan SA; Peddinti G; Airola A; Pahikkala T; Mirtti T; Yu T; Bot BM; Shen L; Abdallah K; Norman T; Friend S; Stolovitzky G; Soule H; Sweeney CJ; Ryan CJ; Scher HI; Sartor O; Xie Y; Aittokallio T; Zhou FL; Costello JC;
Lancet Oncol; 2017 Jan; 18(1):132-142. PubMed ID: 27864015
[TBL] [Abstract][Full Text] [Related]
25. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.
Morton DL; Hsueh EC; Essner R; Foshag LJ; O'Day SJ; Bilchik A; Gupta RK; Hoon DS; Ravindranath M; Nizze JA; Gammon G; Wanek LA; Wang HJ; Elashoff RM
Ann Surg; 2002 Oct; 236(4):438-48; discussion 448-9. PubMed ID: 12368672
[TBL] [Abstract][Full Text] [Related]
26. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
27. Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma.
Signorovitch J; Moshyk A; Zhao J; Le TK; Burns L; Gooden K; Hamilton M
Future Oncol; 2022 Apr; 18(11):1321-1331. PubMed ID: 35048743
[TBL] [Abstract][Full Text] [Related]
28. Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.
Zhong J; Sun W; Hu T; Wang C; Yan W; Luo Z; Liu X; Xu Y; Chen Y
Cancer Med; 2023 May; 12(10):11475-11482. PubMed ID: 37016119
[TBL] [Abstract][Full Text] [Related]
29. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
30. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
31. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors.
Bedikian AY; Legha SS; Mavligit G; Carrasco CH; Khorana S; Plager C; Papadopoulos N; Benjamin RS
Cancer; 1995 Nov; 76(9):1665-70. PubMed ID: 8635073
[TBL] [Abstract][Full Text] [Related]
32. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.
van Zeijl MCT; Haanen JBAG; Wouters MWJM; de Wreede LC; Jochems A; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn EW; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven KJM; van den Eertwegh AJM
J Immunother; 2020 Oct; 43(8):256-264. PubMed ID: 32804914
[TBL] [Abstract][Full Text] [Related]
33. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
Tan AC; Emmett L; Lo S; Liu V; Kapoor R; Carlino MS; Guminski AD; Long GV; Menzies AM
Ann Oncol; 2018 Oct; 29(10):2115-2120. PubMed ID: 30137228
[TBL] [Abstract][Full Text] [Related]
34. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
35. Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
Pires da Silva I; Ahmed T; McQuade JL; Nebhan CA; Park JJ; Versluis JM; Serra-Bellver P; Khan Y; Slattery T; Oberoi HK; Ugurel S; Haydu LE; Herbst R; Utikal J; Pföhler C; Terheyden P; Weichenthal M; Gutzmer R; Mohr P; Rai R; Smith JL; Scolyer RA; Arance AM; Pickering L; Larkin J; Lorigan P; Blank CU; Schadendorf D; Davies MA; Carlino MS; Johnson DB; Long GV; Lo SN; Menzies AM
J Clin Oncol; 2022 Apr; 40(10):1068-1080. PubMed ID: 35143285
[TBL] [Abstract][Full Text] [Related]
36. Prognostic models for predicting relapse or recurrence of major depressive disorder in adults.
Moriarty AS; Meader N; Snell KI; Riley RD; Paton LW; Chew-Graham CA; Gilbody S; Churchill R; Phillips RS; Ali S; McMillan D
Cochrane Database Syst Rev; 2021 May; 5(5):CD013491. PubMed ID: 33956992
[TBL] [Abstract][Full Text] [Related]
37. The Option Value of Innovative Treatments for Metastatic Melanoma.
Thornton Snider J; Seabury S; Tebeka MG; Wu Y; Batt K
Forum Health Econ Policy; 2018 Jun; 21(1):. PubMed ID: 30210050
[TBL] [Abstract][Full Text] [Related]
38. The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.
Ma VT; Daignault-Newton S; Waninger JJ; Journey S; Chopra Z; Tezel A; Redman BG; Fecher LA; Green MD; Alva AS; Lao CD
Pigment Cell Melanoma Res; 2021 May; 34(3):629-640. PubMed ID: 33128316
[TBL] [Abstract][Full Text] [Related]
39. Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma.
Flaherty LE; Liu PY; Unger J; Sondak VK
Am J Clin Oncol; 1997 Dec; 20(6):600-4. PubMed ID: 9391549
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
